FY2026 · ended Jun 30, 2026 · Revenue $43.87M, -19.3% YoY · Filed Sep 25, 2026
Integrated Biopharma, Inc. (INBP) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2026, which ended Jun 30, 2026, it reported revenue of $43.9 million and a net loss of $2.8 million. Free cash flow was $895,000. As of Jun 30, 2026 it held $4.5 million in cash and investments and $3.1 million in total debt.
Revenue
$43.87M
-19.3% vs prior year
Net income
$-2.84M
-451.7% vs prior year
Operating cash flow
$1.24M
-39.9% vs prior year
Free cash flow
$895,000
-52.2% vs prior year
EPS
$-0.09
-400.0% vs prior year
Dividend per share
None
Shares outstanding
31.06M
+0.0% vs prior year
Net cash
$1.39M
FY 2026
Operating margin
-6.2%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- INBP (OTC)
- Fiscal year ends
- June 30
- Incorporated in
- DE
- Headquarters
- Hillside, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1016504
- Former names
- INTEGRATED HEALTH TECHNOLOGIES INC (until Apr 16, 2003); CHEM INTERNATIONAL INC (until May 14, 2002)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2026 Jun 30, 2026 |
FY 2025 Jun 30, 2025 |
FY 2024 Jun 30, 2024 |
FY 2023 Jun 30, 2023 |
FY 2022 Jun 30, 2022 |
|---|---|---|---|---|---|
| Revenue | $43.9M | $54.4M | $50.3M | $50.7M | $56.2M |
| Operating income | -$2.7M | $2.0M | $251,000 | $120,000 | $2.7M |
| Net income | -$2.8M | $808,000 | $112,000 | -$34,000 | $3.8M |
| Diluted EPS | -$0.09 | $0.03 | $0.00 | $0.00 | $0.12 |
| Operating cash flow | $1.2M | $2.1M | $943,000 | $1.2M | $4.1M |
| Free cash flow | $895,000 | $1.9M | $390,000 | $1.1M | $3.6M |
| Total assets | $25.3M | $24.9M | $26.2M | $25.4M | $25.2M |
| Total liabilities | $7.7M | $4.6M | $7.0M | $6.6M | $6.7M |
| Stockholders' equity | $17.7M | $20.3M | $19.2M | $18.9M | $18.6M |
| Cash and investments | $4.5M | $3.6M | $1.7M | $1.3M | $331,000 |
| Total debt | $3.1M | $1.0M | $1.8M | $2.7M | $2.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Sep 25, 2026 | Sep 25, 2026 |
| 10-K | Annual report | Sep 25, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Other events
|
Aug 20, 2026 | Aug 20, 2026 |
| 8-K |
Current report
Material agreement, Agreement ended
|
Jul 2, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
May 8, 2026 | May 8, 2026 |
| 10-Q | Quarterly report | May 8, 2026 | Mar 31, 2026 |
All 557 Integrated Biopharma, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.